Edgewise Therapeutics
EWTX
39.57
-0.45
-1.12%
Edgewise Therapeutics
US · EWTX
#2209 by market cap
Listed 2021
39.57
-0.45
-1.12%
Live - 5344 symbols - heartbeat 452s ago
· 2026-10-08 07:03
Pre-market
39.94
+0.94%
After-hours
40.26
+1.74%
- Market cap
- 4.30B
- P/E (TTM)i
- -21.39
- P/Bi
- 9.59
- EPSi
- -1.63
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on EWTX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.30M | 2.21M | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Research & development | 8.62M | 14.98M | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Operating profit | -9.92M | -17.19M | -43.22M | -71.66M | -114.36M | -158.83M | -191.41M |
| Pretax profit | -9.71M | -17.12M | -42.81M | -67.64M | -100.16M | -133.81M | -167.80M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -9.71M | -17.12M | -42.81M | -67.64M | -100.16M | -133.81M | -167.80M |
| Basic EPS | 0 | 0 | -1 | -1 | -2 | -1 | -2 |
| Diluted EPS | -0.48 | -0.37 | -1.14 | -1.26 | -1.57 | -1.45 | -1.63 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.20M | 9.05M | 9.38M | 12.39M | 11.46M | 14.40M |
| Research & development | 36.76M | 33.56M | 37.48M | 43.59M | 42.65M | 47.55M |
| Operating profit | -45.96M | -42.61M | -46.86M | -55.98M | -54.12M | -61.94M |
| Pretax profit | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -40.80M | -36.12M | -40.67M | -50.22M | -49.01M | -57.33M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | -1 |
| Diluted EPS | -0.43 | -0.34 | -0.39 | -0.47 | -0.46 | -0.53 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 24.04M | 129.65M | 283.77M | 357.00M | 327.00M | 475.48M | 543.39M |
| Cash & ST investments | 23.65M | 129.09M | 280.79M | 351.95M | 318.39M | 470.17M | 530.11M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 24.54M | 131.14M | 285.23M | 367.10M | 340.04M | 486.82M | 552.60M |
| Total current liabilities | 1.13M | 4.34M | 10.52M | 16.59M | 16.77M | 23.86M | 27.37M |
| Short-term debt | -- | -- | -- | 608.00K | 980.00K | 996.00K | 1.01M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 41,394,000.00 | 164,556,000.00 | 10,850,000.00 | 20,385,000.00 | 21,205,000.00 | 27,601,000.00 | 30,346,000.00 |
| Total equity | -16.85M | -33.42M | 274.38M | 346.72M | 318.83M | 459.22M | 522.26M |
| Retained earnings | -17.02M | -34.15M | -76.96M | -144.60M | -244.76M | -378.58M | -546.37M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 443.18M | 603.26M | 573.90M | 543.39M | 509.79M | 471.52M |
| Cash & ST investments | 436.39M | 593.99M | 563.34M | 530.11M | 499.56M | 460.71M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 454.39M | 613.33M | 583.47M | 552.60M | 518.52M | 479.69M |
| Total current liabilities | 21.12M | 20.90M | 21.65M | 27.37M | 22.54M | 29.04M |
| Short-term debt | 1.00M | 1.00M | 1.01M | 1.01M | 1.02M | 1.02M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 24,672,000.00 | 24,263,000.00 | 24,819,000.00 | 30,346,000.00 | 25,319,000.00 | 31,611,000.00 |
| Total equity | 429.72M | 589.07M | 558.65M | 522.26M | 493.20M | 448.08M |
| Retained earnings | -419.37M | -455.49M | -496.16M | -546.37M | -595.38M | -652.71M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.17M | -14.63M | -33.51M | -52.64M | -91.95M | -109.03M | -143.82M |
| Depreciation & amortization | 123.00K | 185.00K | 272.00K | 538.00K | 1.73M | 2.29M | 2.27M |
| Free cash flow | -9.35M | -14.84M | -34.18M | -58.18M | -97.69M | -110.34M | -144.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 186.15M | 129.17M | 52.62M | 239.15M | 187.36M |
| Ending cash balance | 23.65M | 104.92M | 15.57M | 21.99M | 86.10M | 41.67M | 61.15M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -37.87M | -32.58M | -34.78M | -38.59M | -42.54M | -42.47M |
| Depreciation & amortization | 554.00K | 567.00K | 570.00K | 575.00K | 590.00K | 597.00K |
| Free cash flow | -37.91M | -32.63M | -34.87M | -38.67M | -42.80M | -42.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 49.92M | 43.40M | 46.00M | 61.15M | 33.21M | 72.32M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -35.53 | -21.78 | -30.10 | -34.40 | -34.19 |
| ROA %i | -39.55 | -22.00 | -20.56 | -20.74 | -28.33 | -32.37 | -32.29 |
| ROIC %i | -- | -- | -35.87 | -22.75 | -33.87 | -40.30 | -38.66 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -31.20 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 21.24 | 29.86 | 26.97 | 21.53 | 19.50 | 19.93 | 19.85 |
| Quick ratioi | 20.89 | 29.73 | 26.69 | 21.22 | 18.98 | 19.71 | 19.37 |
| Debt / assetsi | -- | -- | 0.00 | 1.20 | 1.59 | 0.97 | 0.72 |
| LT debt / equityi | -- | -- | -- | 1.10 | 1.39 | 0.81 | 0.57 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -30.29 | -27.41 | -30.02 | -34.19 | -38.14 | -38.03 |
| ROA %i | -28.98 | -26.32 | -28.73 | -32.29 | -36.18 | -36.09 |
| ROIC %i | -34.90 | -31.48 | -34.27 | -38.66 | -42.86 | -41.89 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 20.99 | 28.87 | 26.51 | 19.85 | 22.61 | 16.24 |
| Quick ratioi | 20.67 | 28.43 | 26.03 | 19.37 | 22.16 | 15.86 |
| Debt / assetsi | 1.00 | 0.71 | 0.72 | 0.72 | 0.73 | 0.75 |
| LT debt / equityi | 0.83 | 0.57 | 0.57 | 0.57 | 0.56 | 0.57 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:03:21 · For reference only, not investment advice and not tailored to your situation.